These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1679254)

  • 1. Maintenance medication for schizophrenia: strategies for dose reduction.
    Schooler NR
    Schizophr Bull; 1991; 17(2):311-24. PubMed ID: 1679254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The routine use of atypical antipsychotic agents: maintenance treatment.
    Kinon BJ
    J Clin Psychiatry; 1998; 59 Suppl 19():18-22. PubMed ID: 9847048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M
    World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine in the long-term treatment of schizophrenia.
    Kane J
    Br J Psychiatry Suppl; 1999; (37):26-9. PubMed ID: 10211138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuroleptic low-dose long-term strategy and intermittent therapy strategy in chronic schizophrenia--a critical review].
    Hofmann P; Melisch B; Zapotoczky HG; Kulhanek F
    Fortschr Neurol Psychiatr; 1993 Jun; 61(6):195-200. PubMed ID: 8101177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
    Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
    Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot fluphenazine for schizophrenia.
    Adams CE; Eisenbruch M
    Cochrane Database Syst Rev; 2000; (2):CD000307. PubMed ID: 10796340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.